Toripalimab Plus Surgery vs Surgery Alone for Resectable Recurrent Nasopharyngeal Carcinoma
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Nasopharyngeal Carcinoma
- PD-1
- Surgery
- Type
- Interventional
- Phase
- Phase 3
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 70 years
- Gender
- Both males and females
Description
Through multicenter, open-label, randomised clinical trials, patients with resectable locally recurrent nasopharyngeal carcinoma are randomized into salvage surgery plus PD-1 treatment group and salvage surgery alone group. The efficacy and safety of patients between these two groups are compared.
Through multicenter, open-label, randomised clinical trials, patients with resectable locally recurrent nasopharyngeal carcinoma are randomized into salvage surgery plus PD-1 treatment group and salvage surgery alone group. The efficacy and safety of patients between these two groups are compared.
Tracking Information
- NCT #
- NCT04778956
- Collaborators
- First Affiliated Hospital, Sun Yat-Sen University
- Nanfang Hospital of Southern Medical University
- First People's Hospital of Foshan
- Zhongshan People's Hospital, Guangdong, China
- Tenth Affiliated Hospital, Sun Yat-sen University
- Investigators
- Principal Investigator: Ming-Yuan Chen, MD, PhD Sun Yat-sen University
Get Well Soon